Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Last trade$4.44
Day change-$0.03 (-0.67%)
Day range$4.36 – $5.01
Volume2,333,427
Market cap$985M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$986.19M
Price / earnings
—
Price / book
9.14×
Price / sales
—
EV / sales
—
EV / EBITDA
-6.29×
Profitability
Earnings per share
-$0.69
Return on assets
-97.95%
Return on equity
-141.62%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.28×
Current ratio
8.55×
Quick ratio
8.55×
Cash ratio
1.79×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$130.95M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SVRA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$18.54M
$18.99M
$15.57M
$12.53M
$9.63M
$10.66M
$9.25M
$7.85M
Research and development
$24.95M
$21.95M
$23.4M
$20.9M
$20.59M
$20.75M
$19.16M
$23.29M
Total operating expenses
$43.54M
$40.97M
$38.99M
$33.42M
$30.26M
$31.44M
$28.44M
$31.17M
Operating income
-$43.54M
-$40.97M
-$38.99M
-$33.42M
-$30.26M
-$31.44M
-$28.44M
-$31.17M
Interest expense
$505K
$829K
$0
$0
$548K
$921K
$0
$0
Income before taxes
-$42.99M
-$40.23M
-$38.14M
-$32.24M
-$29.56M
-$30.4M
-$27.42M
-$29.04M
Income taxes
$0
$0
-$853K
$0
$0
$0
-$784K
$0
Net income
-$42.99M
-$40.23M
-$37.28M
-$32.24M
-$29.56M
-$30.4M
-$26.64M
-$29.04M
Net income attributable to common shareholders
-$42.99M
-$40.23M
-$37.28M
-$32.24M
-$29.56M
-$30.4M
-$26.64M
-$29.04M
EBITDA
-$43.49M
-$40.94M
-$38.97M
-$33.43M
-$30.22M
-$31.41M
-$28.41M
-$31.14M
Basic earnings per share
-$0.17
-$0.16
-$0.15
-$0.13
-$0.14
-$0.14
-$0.12
-$0.13
Diluted earnings per share
-$0.17
-$0.16
-$0.15
-$0.13
-$0.14
-$0.14
-$0.12
-$0.13
Recent news
Company coverage with links to the original publishers.
Savara Inc. announced that Chief Financial and Administrative Officer Dave Lowrance is stepping down effective July 15, 2026, for health-related reasons. His responsibilities will be split, with Chief Operating Officer Robert Lutz assuming the CFO role while administrative duties are distributed among senior leadership. Lutz brings over two decades of pharmaceutical industry experience and previously served as CFO at iBio and Strongbridge Biopharma.
Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will participate in one-on-one meetings and a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3rd. The company's lead program, MOLBREEVI, is a recombinant human GM-CSF in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).
Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will participate in a fireside chat at the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference on May 19th at 10:00am ET in New York. The company's lead program, MOLBREEVI, is a recombinant human GM-CSF in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).
Savara Inc. announced it received a Day 74 Letter from the FDA indicating no Advisory Committee meeting is planned for MOLBREEVI's Biologics License Application, with a PDUFA target action date of August 22, 2026. The company has submitted a Marketing Authorization Application to the European Medicines Agency and remains on track to submit to the UK's MHRA by end of Q1 2026. MOLBREEVI, a recombinant GM-CSF treatment for autoimmune PAP, has received Fast Track and Breakthrough Therapy designations from the FDA.
Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company, announced that its management team will participate in a fireside chat at the 2026 Citizens Life Sciences Conference on March 11th in Miami, FL. The company is focused on rare respiratory diseases with its lead program MOLBREEVI, a recombinant human GM-CSF in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.